分子モデリング市場

The secondary research process involved comprehensive analysis of scientific databases, peer-reviewed computational chemistry journals, academic publications, and authoritative technology and health organizations. Key sources included the US National Science Foundation (NSF), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), US Food & Drug Administration (FDA) Center for Drug Evaluation and Research, European Medicines Agency (EMA), European Bioinformatics Institute (EMBL-EBI), Cambridge Crystallographic Data Centre (CCDC), Protein Data Bank (PDB), American Chemical Society (ACS), Royal Society of Chemistry (RSC), International Union of Pure and Applied Chemistry (IUPAC), National Center for Supercomputing Applications (NCSA), European High-Performance Computing Joint Undertaking (EuroHPC JU), Organisation for Economic Co-operation and Development (OECD) Science and Technology Indicators, World Intellectual Property Organization (WIPO) Patent Database, and national science foundation reports from key markets including Germany (DFG), UK (UKRI), Japan (JST), and China (NSFC). These sources were used to collect software adoption statistics, regulatory approval data for in-silico drug development, computational research funding trends, patent landscapes for molecular simulation technologies, and market landscape analysis for quantum chemistry software, molecular dynamics platforms, AI-driven drug discovery tools, and cloud-based simulation services.

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, CTOs, VPs of Product Development, heads of computational chemistry, heads of regulatory affairs, and commercial directors from vendors of molecular modeling software, CROs providing simulation services, and suppliers of high-performance computers were examples of supply-side sources. Chief scientific officers, heads of computational drug discovery, directors of medicinal chemistry, bioinformatics leads, and procurement managers from government research labs, academic research centers, contract research organizations, and pharmaceutical and biotechnology companies were examples of demand-side sources. In addition to gathering information on software licensing arrangements, cloud adoption trends, pricing tactics, and the dynamics of academic-industry partnership, primary research verified market segmentation, AI integration timescales, and quantum computing roadmaps.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (30%), Rest of World (8%)

Global market valuation was derived through revenue mapping and software licensing analysis. The methodology included:

Identification of 40+ key software vendors and service providers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across molecular mechanics/dynamics software, quantum chemistry platforms, AI/ML-based predictive modeling tools, and contract modeling services

Analysis of reported and modeled annual revenues specific to molecular modeling portfolios

Coverage of vendors representing 75-80% of global market share in 2024

Extrapolation using bottom-up (license count × ASP by deployment type and region) and top-down (vendor revenue validation) approaches to derive segment-specific valuations for software versus services, drug development versus drug discovery applications, and end-user categories